Compare General Mills, Inc. (GIS) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs Eli Lilly And Co — how do they compare? General Mills, Inc. trades at $37.4 (market cap $20.24B), while Eli Lilly And Co trades at $1,205 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 53.4× General Mills, Inc.'s market cap, and General Mills, Inc. pays the higher dividend (6.43%). Which is the better fit depends on your goals.
| GIS | LLY | |
|---|---|---|
Market Cap | $20.24B | $1.08T |
Sector | Consumer Staples | Health |
52-Week High | $51.11 | $1.24K |
52-Week Low | $32.17 | $639.43 |
Enterprise Value | $33.73B | $1.13T |
Dividend Yield | 6.43% | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $37.26, up 1.0% with a bullish technical signal. The stock shows mixed fundamentals with declining revenue ($19.49B in 2025) and negative net income margin (-0.48%), but maintains strong cash flow from operations ($2.92B). Recent earnings beat expectations in Q3 2025 and Q2 2026, while analyst sentiment remains cautious with 61% hold ratings. The company continues dividend payments and focuses on cost-saving initiatives.
Investment outlook remains balanced with attractive valuation (P/E 9.23) offset by margin pressures. Key opportunities include dividend yield and cost savings program, while risks involve declining profitability and competitive pressures. Wall Street consensus price target of $35.36 suggests limited upside from current levels.
Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.
Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
